Valproic Acid Impurity 13

Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA
Mauro Mozael Hirsch, Iohanna Deckmann, Mellanie Fontes-Dutra, Guilherme Bauer-Negrini, Gustavo Della-Flora Nunes, Walquiria Nunes, Bruna Rabelo, Rudimar Riesgo, Rogerio Margis, Victorio Bambini-Junior, Carmem Gottfried
Food and Chemical Toxicology Volume 115, May 2018, Pages 336-343
 
Bioactivation of a Toxic Metabolite of Valproic Acid, (E)-2-Propyl-2,4-pentadienoic Acid, via Glucuronidation. LC/MS/MS Characterization of the GSH−Glucuronide Diconjugates
Wei Tang and Frank S. Abbott
Chem. Res. Toxicol. 1996, 9, 2, 517–526
 
Chromatographic approaches for the characterization and quality control of therapeutic oligonucleotide impurities
N. M. El Zahar  N. Magdy  A. M. El‐Kosasy  Michael G. Bartlett
Biomedical Chromatography Volume32, Issue1 Special Issue: 2018 Special Review Issue January 2018 e4088
 
A validated stability‐indicating gas chromatography method for determination of divalproex sodium impurities in pharmaceutical preparation
Acharya Subasranjan  Pulluru Suresh  C. Srinivasulu  Raoutray Hemant
Drug Testing and Analysis Volume2, Issue4 April 2010 Pages 182-187

Valproic Acid Impurity 13 is chemically Diethyl 2,2-dipropylmalonate. Valproic Acid Impurity 13 is supplied with detailed characterization data compliant with regulatory guideline. Valproic Acid Impurity 13 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Valproic Acid.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.